Septerna (SEPN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jul, 2026Opening remarks and agenda
The meeting was called to order by the CFO, who also served as chairman and secretary, with the chief legal officer taking minutes.
The meeting was held virtually to facilitate broader stockholder participation.
The agenda included formal business as described in the proxy statement, with questions limited to official business.
Board and executive committee updates
Current board members and executive officers were introduced, including the CEO, President/COO, CFO, and other key leaders.
Corporate governance
Ernst & Young LLP was present as the independent registered public accounting firm, and an Inspector of Election was appointed.
Only validated stockholders could vote and ask questions via the virtual platform.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Septerna
- Q1 PTH1R data and the oral TSHR program anchor a pipeline funded into mid-2029.SEPN
Stifel 2026 Healthcare Conference 2026 - SEP-479 and SEP-204 target 2027 clinical milestones, with cash runway through mid-2029.SEPN
3rd Annual Guggenheim Healthcare Innovation Conference - $565.2M in liquidity supports pipeline investment, with SEP-479 data expected in Q1 2027.SEPN
Q3 2026 - Advancing GPCR-targeted therapies in endocrine and metabolic diseases, with SEP-479 leading in phase I.SEPN
12th Annual Cantor Fitzgerald Global Healthcare Conference - Oral PTH agonist phase I data expected Q1, with pipeline progress in Graves', osteoporosis, and mast cell diseases.SEPN
Wells Fargo 21st Annual Healthcare Conference - Advancing oral small molecule GPCR therapies with robust pipeline and major Novo Nordisk partnership.SEPN
Investor presentation - Q2 2026 revenue reached $26.7M, net loss narrowed, and cash runway extends into 2029.SEPN
Q2 2026 - Advancing oral therapies for endocrine and immunological diseases via innovative GPCR targeting.SEPN
44th Annual J.P. Morgan Healthcare Conference - Rapid GPCR drug discovery platform advances oral therapies with key data expected in 2025.SEPN
43rd Annual J.P. Morgan Healthcare Conference 2025